# MSL FIELD INTELLIGENCE SURVEY
## CDK4/6 Inhibitor Formulary & Prescribing Patterns

---

## üéØ PURPOSE

**Complement FOI requests with qualitative field intelligence:**
- FOI tells us "What's on formulary?"
- MSL surveys tell us "What do oncologists actually prescribe and why?"

**Target:** 20-30 breast cancer oncologists across 10 priority trusts  
**Timeline:** 4-6 weeks  
**Method:** In-person MSL visits or phone interviews

---

## üìã MSL SURVEY SCRIPT

### **Introduction:**

*"Thank you for taking time today. As part of our ongoing support for breast cancer treatment, we're gathering insights on CDK4/6 inhibitor use patterns. This will help us better support clinicians like yourself. This should take about 5-10 minutes."*

---

### **SECTION 1: FORMULARY STATUS**

**Q1. Which CDK4/6 inhibitors are currently available on your trust formulary?**

- [ ] Palbociclib (Ibrance)
- [ ] Ribociclib (Kisqali)
- [ ] Abemaciclib (Verzenio)
- [ ] None of the above (explain: ______________________)

**Q2. For each drug available, how is it positioned?**

| Drug | First-line | Second-line/Alternative | Restricted | Not listed |
|------|-----------|-------------------------|----------|------------|
| Ibrance (palbociclib) | ‚òê | ‚òê | ‚òê | ‚òê |
| Kisqali (ribociclib) | ‚òê | ‚òê | ‚òê | ‚òê |
| Verzenio (abemaciclib) | ‚òê | ‚òê | ‚òê | ‚òê |

**Q3. If any drug is restricted, what are the restrictions?**

- [ ] Prior authorization required
- [ ] Consultant-only prescribing
- [ ] Second-line only (after alternative CDK4/6 inhibitor)
- [ ] Specific patient criteria (specify: ______________________)
- [ ] Other (specify: ______________________)

---

### **SECTION 2: PRESCRIBING BEHAVIOR**

**Q4. In your practice, which CDK4/6 inhibitor do you use most often for first-line therapy in HR+/HER2- advanced breast cancer?**

- [ ] Palbociclib (Ibrance) - ____% of patients
- [ ] Ribociclib (Kisqali) - ____% of patients
- [ ] Abemaciclib (Verzenio) - ____% of patients
- [ ] Varies based on patient factors - ____% each

**Q5. What factors influence your choice of CDK4/6 inhibitor?** (Select all that apply)

- [ ] Formulary preference/availability
- [ ] Clinical trial data (OS, PFS)
- [ ] Side effect profile
- [ ] Dosing schedule (convenience)
- [ ] Patient preference
- [ ] Cost/budget considerations
- [ ] Personal experience/comfort
- [ ] Colleague recommendations
- [ ] Other (specify: ______________________)

**Q6. How familiar are you with the MONALEESA trial data for Kisqali?**

- [ ] Very familiar (have read primary publications)
- [ ] Somewhat familiar (aware of key findings)
- [ ] Minimally familiar (heard of it)
- [ ] Not familiar

**Q7. Does Kisqali's overall survival benefit influence your prescribing decisions?**

- [ ] Yes, it's a major factor
- [ ] Somewhat - I consider it along with other factors
- [ ] No, other factors are more important
- [ ] Not aware of OS benefit

---

### **SECTION 3: BARRIERS & OPPORTUNITIES**

**Q8. Are there any barriers to using Kisqali at your trust?**

- [ ] Not on formulary
- [ ] Restricted access / prior authorization
- [ ] Unfamiliarity with the drug
- [ ] Cost concerns
- [ ] Prefer to use more established option (Ibrance)
- [ ] Side effect concerns
- [ ] No significant barriers
- [ ] Other (specify: ______________________)

**Q9. What would increase your use of Kisqali?** (Select all that apply)

- [ ] Easier formulary access
- [ ] More clinical data/education
- [ ] Peer recommendations/case studies
- [ ] Better side effect management support
- [ ] Patient assistance programs
- [ ] Cost parity with Ibrance
- [ ] Nothing - already using as appropriate
- [ ] Other (specify: ______________________)

**Q10. Have you switched any patients from Ibrance/Verzenio to Kisqali, or vice versa?**

- [ ] Yes - Ibrance ‚Üí Kisqali (Reason: ______________________)
- [ ] Yes - Verzenio ‚Üí Kisqali (Reason: ______________________)
- [ ] Yes - Kisqali ‚Üí Ibrance (Reason: ______________________)
- [ ] Yes - Kisqali ‚Üí Verzenio (Reason: ______________________)
- [ ] No, I haven't switched between CDK4/6 inhibitors

---

### **SECTION 4: TRUST CONTEXT**

**Q11. Approximately how many HR+/HER2- advanced breast cancer patients do you treat per year?**

- [ ] <10 patients
- [ ] 10-25 patients
- [ ] 26-50 patients
- [ ] 51-100 patients
- [ ] >100 patients

**Q12. Does your trust have a multidisciplinary tumor board (MDT) that discusses CDK4/6 inhibitor selection?**

- [ ] Yes - regular discussion
- [ ] Yes - occasional discussion
- [ ] No - individual clinician decision

**Q13. Who primarily influences formulary decisions at your trust?**

- [ ] Pharmacy & Therapeutics Committee
- [ ] Oncology consultant consensus
- [ ] Clinical director / service lead
- [ ] Budget/finance considerations
- [ ] ICB-level decisions
- [ ] Don't know

---

### **SECTION 5: FUTURE ENGAGEMENT**

**Q14. Would you be interested in any of the following?** (Select all that apply)

- [ ] Advisory board participation
- [ ] Real-world data collaboration
- [ ] Educational speaker opportunity
- [ ] Case study publication
- [ ] Clinical trial collaboration
- [ ] Patient support program information
- [ ] None of the above

**Q15. Any additional comments about CDK4/6 inhibitor use at your trust?**

_________________________________________________________

_________________________________________________________

---

### **Thank you & Close:**

*"Thank you very much for your time and insights. This information is extremely valuable for understanding real-world treatment patterns. Would it be helpful if I shared some recent MONALEESA trial updates or case studies with you?"*

---

## üìä DATA ANALYSIS FRAMEWORK

### **After collecting 20-30 responses:**

**1. Formulary Status Summary**
- Create matrix: Trust √ó Drug √ó Status (First-line/Alternative/Restricted)
- Compare: How many trusts position Kisqali as first-line vs alternative?

**2. Market Share Estimates**
- Average % of patients receiving each CDK4/6 inhibitor
- By trust: Identify high-Kisqali vs high-Ibrance trusts

**3. Barrier Analysis**
- Most common barriers to Kisqali use
- Rank: Formulary > Cost > Familiarity > Side effects?

**4. Opportunity Sizing**
- Trusts with high patient volume + low Kisqali use = priority targets
- Trusts with "No significant barriers" = expansion opportunities

**5. KOL Identification**
- High-volume prescribers (>50 patients/year) = KOL targets
- Advisory board interest = engagement opportunities

---

## üéØ TARGET RESPONDENT PROFILE

**Ideal Survey Participants:**

**Profile:**
- Consultant medical oncologist
- Breast cancer specialist
- Prescribes CDK4/6 inhibitors regularly
- Works at one of 10 priority trusts

**How to Identify:**
- Trust oncology department directories
- Conference speaker lists (UK breast cancer meetings)
- PubMed authors with trust affiliations
- Existing MSL relationship database

**Recruitment:**
- MSL cold outreach: "Would you have 10 minutes to discuss CDK4/6 inhibitor use patterns?"
- Existing relationships: "Could I get your feedback on something?"
- Advisory board candidates: "We're gathering field insights..."

---

## üîÑ COMBINING MSL + FOI DATA

| Intelligence Source | FOI Request | MSL Survey |
|---------------------|-------------|------------|
| **Timeline** | 8 weeks | 4-6 weeks |
| **Data Type** | Quantitative | Qualitative |
| **Coverage** | 50 trusts | 20-30 oncologists (10 trusts) |
| **Tells You** | Official formulary status | Real prescribing behavior |
| **Strength** | Systematic, documented | Context, "why" behind decisions |
| **Weakness** | Doesn't capture prescriber behavior | Small sample size |

**Best Practice:** Use both

**Example Combined Insight:**
- FOI: "Kisqali is listed as 'alternative' at Trust X"
- MSL: "But 3 of 4 oncologists surveyed at Trust X use it first-line anyway"
- Action: Formulary upgrade submission has internal support

---

## üìà EXPECTED INTELLIGENCE OUTPUT

**After 6-8 weeks:**

‚úÖ **Formulary Map:** 50 trusts with CDK4/6 positioning  
‚úÖ **Prescribing Patterns:** Real-world Kisqali vs Ibrance usage by trust  
‚úÖ **Barrier Analysis:** Top 5 barriers to Kisqali adoption  
‚úÖ **Opportunity Matrix:** Trust-level targets ranked by potential  
‚úÖ **KOL Database:** 20-30 engaged breast cancer oncologists  

**Strategic Actions Enabled:**
1. Target formulary submissions at trusts where Kisqali is "alternative"
2. Focus MSL education on trusts with low familiarity
3. Address specific barriers (cost, side effects, data gaps)
4. Recruit advisory board from high-engagement respondents
5. Publish real-world data from supportive KOLs

---

## ü§ñ OPENCLAW AUTOMATION

**For production implementation:**

```python
# Automated MSL survey analysis

def analyze_survey_responses(responses):
    # Aggregate formulary status by trust
    formulary_matrix = create_trust_drug_matrix(responses)
    
    # Calculate market share estimates
    market_share = estimate_market_share(responses)
    
    # Identify barriers by frequency
    barriers = rank_barriers(responses)
    
    # Score trust opportunity
    opportunities = score_trust_opportunities(
        patient_volume=responses['Q11'],
        current_usage=responses['Q4'],
        barriers=responses['Q8']
    )
    
    # Generate action plan
    action_plan = {
        'high_priority_trusts': opportunities[:10],
        'formulary_targets': [t for t in trusts if kisqali_is_alternative(t)],
        'education_needs': [t for t in trusts if low_familiarity(t)],
        'kol_candidates': [r for r in responses if high_volume(r) and advisory_interest(r)]
    }
    
    return action_plan
```

**Cron job:**
- Weekly: Reminder to MSL team for survey completion targets
- Monthly: Analysis of accumulated responses
- Quarterly: Trend analysis (is Kisqali share growing?)

---

## ‚úÖ NEXT STEPS

**This Week:**
1. Share survey template with MSL team
2. Identify 30 target oncologists (3 per priority trust)
3. Set MSL targets: 20-30 completed surveys in 6 weeks
4. Create tracking spreadsheet for responses

**Week 2-6: Execution**
- MSLs conduct surveys during regular visits
- Weekly check-ins: How many responses collected?
- Adjust approach if low response rate

**Week 7-8: Analysis**
- Aggregate data
- Generate trust-level opportunity matrix
- Combine with FOI request data
- Present findings to brand team

---

**Result:** Complete intelligence picture combining official formulary status (FOI) with real-world prescribing behavior (MSL surveys).

ü¶æ **OpenClaw Trust Intelligence Engine**
